| Literature DB >> 28529481 |
Kislay Roy1, Prasad Neerati, Chun Hei Antonio Cheung2, Rupinder K Kanwar1, Rajat Sandhir3, Jagat R Kanwar1.
Abstract
Alkali burn injury is a true ocular emergency of the conjunctiva and cornea that requires immediate precision. Lack of an immediate therapy can lead to a substantial damage in the ocular surface and anterior segment further causing visual impairment and disfigurement. We explored the regenerative capability of dominant negative survivin protein (SurR9-C84A) and histone deacetylase inhibitor trichostatin-A (TSA) in vivo, in a rat alkali burn model. A topical insult in rat eyes with NaOH led to degradation of the conjunctival and corneal epithelium. The integrity of the conjunctival and corneal tissue was increased by TSA and SurR9-C84A by improving the clathrin and claudin expressions. Wound healing was initiated by an increase in TGF-beta-1 and, increased endogenous survivin which inhibited apoptosis post-TSA and SurR9-C84A treatments. Protein expressions of fibronectin and alpha-integrin 5 were found to increase promoting corneal integrity. The cytokine analysis confirmed increased expressions of IL-1beta, IL-6, IL-12, IL-13, IFN-gamma, TNF-alpha, GMCSF, Rantes, and MMP-2 in injured cornea, which were found to be significantly downregulated by the combined treatment of SurR9-C84A and TSA. The ocular and systemic pharmacokinetic (PK) parameters were measured post-topical ocular administration of TSA and SurR9-C84A. The SurR9-C84A and TSA sustained relatively longer in the cornea, conjunctiva, and aqueous humor than in the tear fluid and plasma. Our results confirmed that a combination of TSA with SurR9-C8A worked in synergy and showed a promising healing and anti-inflammatory effect in a very short time against alkali burn. Therefore, a combination of TSA and SurR9-C84A can fulfill the need for an immediate response to wound healing in alkali burnt cornea. We also synthesized ultra-small chitosan nanoparticles (USC-NPs) targeted with alpha-SMA antibodies that can be used for delivery of TSA and SurR9-C84A specifically to the ocular burn site.Entities:
Keywords: cytokines; haze; scarring; survivin; trichostatin-A; wound healing
Year: 2017 PMID: 28529481 PMCID: PMC5418359 DOI: 10.3389/fphar.2017.00223
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Measure of opacity, permeability, and irritation.
| Treatment | Mean opacity measurement | Mean permeability measurement | Mean | Predicted irritation potential |
|---|---|---|---|---|
| Control eye | 0.0 | 0.0 | 0.0 | No irritation |
| Alkali burn (NaOH) | 2.5 ± 0.5∗∗ | 0.80 ± 0.5∗∗ | 10.2 ± 0.5∗∗∗ | Moderate irritation |
| NaOH–TSA | 0.5 ± 0.2 ∗ | 0.15 ± 0.5∗ | 0.20 ± 0.5∗ | No irritation |
| NaOH–SuR9-C84A | 0.0∗ | 0.0∗ | 0.0∗ | No irritation |
| NaOH–SuR9-C84A+TSA | 0.0∗ | 0.0∗ | 0.0∗ | No irritation |
Concentration of TSA in tissues and plasma after topical application in eye.
| Time (min) | Plasma (ng/mL, mean ± | Aqueous humor (ng/mL, mean ± | Cornea (μg/g, mean ± | Conjunctiva (μg/g, mean ± | Tear fluid (μg/g, mean ± |
|---|---|---|---|---|---|
| 2 | 103.61 ± 28.37 | 119.43 ± 37.92 | 216.83 ± 78.05 | 267.88 ± 75.51 | 333.42 ± 69.72 |
| 10 | 263.87 ± 80.96 | 112.94 ± 15.10 | 291.02 ± 109.25 | 261.29 ± 66.47 | 208.93 ± 30.82 |
| 30 | 109.16 ± 33.00 | 62.80.24 ± 7.29 | 762.86 ± 385.68 | 178.23 ± 35.22 | 154.98 ± 73.25 |
Pharmacokinetics of TSA in rat eye tissues and plasma after topical application.
| Pharmacokinetic parameters | Plasmaa | Aqueous humorb | Cornea | Conjunctiva | Tear fluid |
|---|---|---|---|---|---|
| 160.3 ± 61.0 | 11,046 ± 2734 | 44.67 ± 12.91 | 26.26 ± 7.19 | 2,987 ± 1814 | |
| 0.167 | 0.333 | 0.0833 | 0.0833 | 0.0833 | |
| 1.5 | 1.5 | 3.5 | 4.2 | 2.3 | |
| CL/ | 12.6 | 0.5 | 7.5 | 11.5 | 1.0 |
| 34.5 | 0.6 | 35.5 | 45.5 | 2.0 | |
| AUC0-8 (μg h/g) | 65.5 | 7568 | 45.5 | 53.4 | 678.5 |
| AUC0-∞ (μg h/g) | 68.4 | 7689 | 55.5 | 51.70 | 768.5 |
Blood analysis.
| Parameters | Untreated | NaOH | NaOH–TSA | NaOH–SurR9-C84A | NaOH–TSA–SurR9-C84A |
|---|---|---|---|---|---|
| WBC | 8.15 ± 2.02 | 3.4 ± 1.19 | 5.48 ± 2.06 | 1.3 ± 3.18 | 8.8 ± 2.43 |
| RBC | 9.10 ± 0.41 | 6.53 ± 2.89 | 8.15 ± 0.61 | 8.35 ± 0.99 | 9.51 ± 0.82 |
| HGB | 18.66 ± 1.01 | 14.61 ± 5.35 | 17.61 ± 1.41 | 17.1 ± 1.11 | 18.75 ± 1.69 |
| HCT | 50.71 ± 2.36 | 40.71 ± 1.76 | 46.2 ± 4.14 | 46.85 ± 4.14 | 52.98 ± 4.07 |
| MCV | 55.66 ± 0.51 | 62.5 ± 8.01 | 56.66 ± 1.86 | 55.66 ± 1.86 | 47.5 ± 2.08 |
| MCH | 20.5 ± 0.55 | 23.45 ± 4.36 | 21.63 ± 1.01 | 20.36 ± 1.42 | 19.73 ± 0.70 |
| MCHC | 36.81 ± 1.39 | 37.51 ± 4.79 | 38.15 ± 1.63 | 36.61 ± 1.57 | 35.58 ± .04 |
| PLT | 334.16 ± 116 | 487 ± 166 | 256.33 ± 117 | 547.16 ± 130 | 409.66 ± 135 |